The elephant in the room with AstraZeneca’s latest update

The AstraZeneca share price jumped over 5% on a trading update last week, but there’s a big reason to avoid the stock, argues G A Chester.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The AstraZeneca (LSE: AZN) share price jumped 5.5% after releasing its Q3 trading update last week. The FTSE 100 pharma giant said: “The third quarter again saw all three therapy areas and every sales region produce encouraging performances.” Management upgraded its full-year sales guidance to an increase by “a low to mid-teens percentage” from its prior guidance of “a low double-digit percentage.”

Bulls have been buoyed by the update but, for me, it highlights what I think is an elephant in the room. This particular pachyderm has been hiding in plain sight in the AZN atrium for several years, growing bigger all the time. Let me show you how it’s developed, and how I think it impacts the valuation of the company.

Smoke and mirrors

Earlier this month, AZN announced it’s agreed to sell the commercial rights for Losec for $243m. Now, you might think the one-off gain from the sale of this non-core asset would be excluded from its core operating performance as an exceptional item. Not a bit of it. AZN includes such “gains on disposal of intangible assets” in its core numbers. The table below shows their contribution to total core operating profit over the last five years.

Should you invest £1,000 in AstraZeneca right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if AstraZeneca made the list?

See the 6 stocks

 

2014

2015

2016

2017

2018

Total core operating profit ($bn)

6.9

6.9

6.7

6.8

5.7

Core operating profit before gains on disposals ($bn)

6.9

5.9

5.4

5.3

3.8

Gains on disposals ($bn)

0.0

1.0

1.3

1.5

1.9

Gains on disposals as percentage of total core operating profit

0

14

19

22

33

As you can see, gains on disposals of drugs AZN has deemed no longer core to the business have made an increasing contribution to core operating profit. Such disposals have gone from £0 in 2014 to £1.9bn in 2018, the latter representing a whopping 33% of total core operating profit. At the same time, what I view as the true core operating profit (before gains on non-core disposals) has fallen each and every year from £6.9bn in 2014 to £3.8bn in 2018.

A cynic might say AZN has used non-core disposals to try to maintain core operating profit, and keep investors onside, while it waits for real operating profit to come through from new drugs. In other words, it’s employed smoke-and-mirrors accounting.

Crystal ball

Happily for the company, it looks nailed-on that 2019’s core profit (before gains on non-core disposals) will increase for the first time in five years — i.e. be higher than 2018’s $3.8bn — and gains on non-core disposals will be lower than 2018’s $1.9bn.

Last week’s Q3 update told us total core operating profit for the year to date is up 41% at $4.9bn, while core ‘other operating income’, the lion’s share of which will be gains on non-core disposals, is down 7% at $1.1bn.

Looking into my crystal ball, I can see AZN posting investor-friendly strong and steady core earnings growth in the coming years, built on rising real core profits from new drugs and a managed decline in the contribution of non-core disposals, deflating the elephant in the room. However, if AZN runs out of non-core assets to sell — or willing buyers — before real core earnings have increased sufficiently, investors could be in for a nasty shock.

At a share price of 7,383p, the company is trading at a whopping 41 times my calculation of real 2018 core earnings of around 180p a share. As such, I’m inclined to avoid the stock until I’ve seen the extent to which real earnings have risen and non-core disposals have deflated in 2019.

Like buying £1 for 31p

This seems ridiculous, but we almost never see shares looking this cheap. Yet this Share Advisor pick has a price/book ratio of 0.31. In plain English, this means that investors effectively get in on a business that holds £1 of assets for every 31p they invest!

Of course, this is the stock market where money is always at risk — these valuations can change and there are no guarantees. But some risks are a LOT more interesting than others, and at The Motley Fool we believe this company is amongst them.

What’s more, it currently boasts a stellar dividend yield of around 10%, and right now it’s possible for investors to jump aboard at near-historic lows. Want to get the name for yourself?

See the full investment case

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any of the shares mentioned. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Concept of two young professional men looking at a screen in a technological data centre
Investing Articles

Why Warren Buffett fears AI – and where savvy investors could spot an opportunity

Warren Buffett is cautious about AI but this Fool thinks the technology could present unique opportunities for forward-thinking investors.

Read more »

Storytelling image of a multiethnic senior couple in love - Elderly married couple dating outdoors, love emotions and feelings
Investing Articles

Is the 12.3% yield on this UK dividend stock too good to be true?

The impressive double-digit yield on this dividend stock recently grabbed the attention of our writer. But how sustainable is it?

Read more »

Investing Articles

2 dividend growth stocks analysts think are strong buys right now

Growth stocks that also distribute cash offer investors the best of both worlds. Stephen Wright looks at two that have…

Read more »

Investing Articles

I asked Anthropic’s Claude for the best FTSE 100 stock to buy right now. I’m impressed with what it said

Can artificial intelligence identify the best FTSE 100 stock to buy right now? Stephen Wright tried it out – and…

Read more »

Investing Articles

£1k in savings? Here’s how investors can aim to turn that into a £9,600-a-year second income

Harvey Jones invests small, regular sums in FTSE 100 dividend stocks in an attempt to build a second income stream…

Read more »

Runner standing at the starting point with 2025 year for starting in new year 2025 to achieve business planing and success concept.
Investing Articles

5 investment trusts to consider for a new 2025 ISA

The biggest challenge when starting an ISA is choosing which stocks to buy. Investment trusts can make it a whole…

Read more »

Smart young brown businesswoman working from home on a laptop
Investing Articles

Have I left it too late to buy Nvidia shares?

When the whole world was racing to buy Nvidia shares, Harvey Jones decided they were overhyped. Does the recent dip…

Read more »

Dividend Shares

I asked ChatGPT to pick me the best passive income stock. Here’s the result!

Jon Smith tries to make friends with ChatGPT and critiques the best passive income pick the AI tool suggested for…

Read more »